Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapies for unmet medical needs in the US. They offer LUPKYNIS to treat adult lupus nephritis patients. They have a collaboration agreement with Otsuka Pharmaceutical Co., Ltd. Founded in 1993, Aurinia is headquartered in Edmonton, Canada.
Overview
Strengths
- Strong EBITDA Margin of 23.32%.
Weaknesses
- With a depreciation Potential of -54.73%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (296.12) is significantly higher than the sector mean (91.15).
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- EV/EBIT (138.34) is significantly higher than the sector mean.
Key Financial Data
| Indicator | Value |
|---|
| PER | 299.3 |
| EV/EBITDA | 31.3 |
| Price/Free Cash Flow' | 39.0 |
| ROIC | 9.7% |
| Net Debt/EBITDA | 100.0 |